Leicester Doctor's Mounjaro Experience: Mental Changes & Advice
In a candid account, Dr. Sachin Khunti, a 33-year-old doctor from Leicester, reveals his personal journey with Mounjaro (tirzepatide), the popular GLP-1/GIP receptor agonist used for weight management in obesity. Meeting clinical criteria for obesity as a South Asian male with elevated LDL cholesterol and a strong family history of cardiometabolic disease, Dr. Khunti started the medication under medical supervision—not for aesthetics, but to address real medical risks. His experience highlights not just physical weight loss, but profound psychological shifts that anyone considering Mounjaro should know about.
Dr. Khunti's Starting Point and Initial Results
Before beginning Mounjaro, Dr. Khunti weighed just under 15st 4lb with a 38.5-inch waist. After three months on the drug, he dropped to 13st 1lb and reduced his waist to 35 inches—a loss of almost two stone. This rapid progress was impressive, but what truly stood out were the mental and behavioral changes.
"What surprised me most while taking it was how quiet food noise became, the constant background thoughts about food were noticeably reduced," said Dr. Khunti.
His friends and family also noticed shifts in his appetite and mood. While on treatment, he had significantly less interest in snacking or alcohol. Compared to previous weight loss attempts through calorie restriction alone, he felt more stable and less irritable—changes his wife definitely appreciated.
How Mounjaro Works: Understanding the Mechanism Behind Food Noise Reduction
Mounjaro, or tirzepatide, is a dual agonist that mimics GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormones. These regulate blood sugar, slow gastric emptying, and signal fullness to the brain, effectively dialing down the persistent 'food noise'—those intrusive thoughts about eating that plague many with obesity. For patients like Dr. Khunti, this translates to reduced cravings not just for food, but even alcohol, as the brain's reward pathways are modulated. Clinical trials support these effects, showing tirzepatide's superiority in appetite suppression over single GLP-1 agonists like semaglutide (Ozempic/Wegovy).
The Reality of Stopping Mounjaro: Rapid Return of Cravings
After three months, Dr. Khunti stopped the medication, only to see the benefits reverse quickly. Within two months, his weight rose to 85.5kg and his waist to 36.3 inches. Cravings returned swiftly, especially during social events or stress.
"What surprised me most after stopping was how quickly appetite signals and cravings returned... It reinforced for me that obesity biology does not simply disappear, and that long-term strategy is essential."
This rebound underscores obesity as a chronic condition, akin to hypertension or diabetes, where discontinuation often leads to regain without sustained lifestyle changes. Dr. Khunti has since restarted treatment at a 5mg dose under medical supervision, stabilizing at approximately 83kg.
Side Effects Dr. Khunti Experienced
During the early weeks, he encountered mild nausea, constipation, and reflux—common gastrointestinal side effects of GLP-1/GIP therapies due to delayed stomach emptying. These typically improve over time, but monitoring is key. Tools like Shotlee can help patients track these symptoms alongside medication schedules for better doctor discussions.
A Doctor's Deeper Empathy and Holistic Advice
Taking Mounjaro himself has transformed Dr. Khunti's perspective. "It has strengthened my understanding of the lived experience, particularly the impact on appetite regulation and food noise," he shared. He emphasizes that medication alone isn't enough:
